Pollen Allergy Clinical Trial
Official title:
Comparison of the Efficacy and the Safety of Different Schedules of Administration of Sub-lingual Immunotherapy in Patients With Ragweed Pollinosis: a Phase III Randomized and Controlled Clinical Study
The dose and the mode of administration of sublingual therapy remain open questions to determine the efficacy and safety of this desensitization therapy, the main purpose of this study is to evaluate if different routes of administration (oral-vestibular vs. sublingual) and a maximum dose of allergen administered are able to determine a different effect or a different incidence of side effects of the therapy in a group of patients with rhinoconjunctivitis and/or asthma due to ragweed
Version 1 16/02/2011 The allergen-specific immunotherapy represents an important therapeutic
option for the treatment of allergic respiratory diseases. Its clinical efficacy is well
demonstrated, although the mechanism of action is still under study.
The main purpose of immunotherapy is to induce an allergen-specific tolerance so that the
natural exposure to the allergen does not cause clinical symptoms.
The clinical efficacy of standard subcutaneous immunotherapy (SCIT) is known. A
meta-analysis Cochrane on the clinical efficacy of SCIT in allergic rhinitis 51 double-blind
studies with a total 2871 patients) demonstrated a reduction in symptoms in 73% of patients
and a reduction in the use of drugs in 57%.
Other studies also show that SCIT was effective in the long term (at least 3-5 years of
suspension) reduces sensitization to new allergens, prevents progression of allergic
rhinitis in asthma and significantly improves the symptoms of asthma, hyper- bronchial
reactivity and the use of asthma medications.
Sublingual immunotherapy (SLIT) represents an effective alternative route of administration
of vaccine therapy with an allergic profile security than the SCIT.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT03727399 -
Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients
|
||
| Completed |
NCT00263627 -
Safety and Efficacy of Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of Birch Pollen Allergens
|
Phase 3 | |
| Terminated |
NCT04874714 -
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 3 | |
| Completed |
NCT04622917 -
Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.
|
Phase 4 |